Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978639 | 0.81 | KDM1A (0.37) | PTGDR2 | |
| SCHEMBL980913 | 0.73 | EGFR (0.31) | PTGDR2 | |
| SCHEMBL979774 | 0.69 | ACACB (0.34) | PTGDR2KDR | |
| SCHEMBL979169 | 0.69 | KDM1A (0.36) | PTGDR2 | |
| SCHEMBL980982 | 0.63 | TP53 (0.30) | — | |
| SCHEMBL981048 | 0.62 | TP53 (0.33) | — | |
| SCHEMBL978620 | 0.60 | TP53 (0.34) | PTGDR2 | |
| SCHEMBL8404471 | 0.58 | — | — | |
| SCHEMBL15871038 | 0.57 | LPO (0.48) | PTGDR2KDR | |
| SCHEMBL980908 | 0.57 | SMN1; SMN2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456765-B1 | IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-05-01 | — | — | EP | claimed |
| US-8334287-B2 | Imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-12-18 | — | — | US | claimed |
| EP-2456765-A1 | IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-05-30 | — | — | EP | claimed |
| WO-2011006910-A1 | IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-20 | — | — | WO | claimed |
| US-20110015202-A1 | IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-20 | — | — | US | claimed |
| EP-2456765-B1 | IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-05-01 | — | — | EP | disclosed |
| US-8334287-B2 | Imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-12-18 | — | — | US | disclosed |
| EP-2456765-A1 | IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011006910-A1 | IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015202-A1 | IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015202-A1 | IMIDAZOLES | GRM5, GRM1, GRIK5 | PTGDR2 179/4885KDR 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.